Skip to main content
SpringerLink
Log in

Randomized, controlled study on adjuvant immunochemotherapy with PSK® in curatively resected colorectal cancer

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

A randomized, controlled trial of adjuvant immunochemotherapy with PSK ® (Kureha Chemical Industry Co., Tokyo, Japan) in curatively resected colorectal cancer was studied in 35 institutions in the Kanagawa prefecture. From March 1985 to February 1987, 462 patients were registered. Four hundred forty-eight of those patients (97.0 percent) satisfied the eligibility criteria. The control group received mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) administration for over six months. The PSK ® group received PSK ® orally for over three years, in addition to mitomycin C and 5-FU as in the control group. At the end of February 1990, the median follow-up time for this study was four years (range, three to five years). The disease-free survival curve and the survival curve of the PSK ® group were better than those of the control group, and differences between the two groups were statistically significant (disease-free survival,P =0.013; survival,P =0.013). These results indicate that adjuvant immunochemotherapy with PSK ® was beneficial for curatively resected colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. SAS Institute Inc. SAS user's guide: statistics. 5th ed. Cary, NC: SAS Institute, 1985.

    Google Scholar 

  2. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457–81.

    Google Scholar 

  3. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.

    PubMed  Google Scholar 

  4. Buyse M, Zeleniuchi-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988;259:3571–8.

    PubMed  Google Scholar 

  5. Hattori T, Nakajima T, Nakazato H. Postoperative adjuvant immunochemotherapy with Mitomycin C, Tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 1990;20:127–36.

    PubMed  Google Scholar 

  6. Mavlight GM, Gutterman JU, Burges MA,et al. Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil. Lancet 1976;1:871–5.

    PubMed  Google Scholar 

  7. Falk RE, MacGregor AB, Landi S,et al. Immunostimulation with intraperitoneally administered Bacille Calamette Guérin for advanced malignant tumors of gastrointestinal tract. Surg Gynecol Obstet 1976;142:363.

    PubMed  Google Scholar 

  8. Valdivieso M, Bedikian A, Burgess MA,et al. Chemoimmunotherapy of metastatic large bowel cancer. Cancer 1977;40:2731–9.

    PubMed  Google Scholar 

  9. Windle R, Bell PR, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987;74:569–72.

    PubMed  Google Scholar 

  10. Laurie JA, Moertel CG, Fleming TR,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447–56.

    PubMed  Google Scholar 

  11. Moertel CG, Fleming TR, Macdonald JS,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.

    PubMed  Google Scholar 

  12. Tsukagoshi S, Hashimoto Y, Fujii G,et al. Krestin (PSK). Cancer Treat Rev 1984;11:131–55.

    Google Scholar 

  13. Kamisato JK, Nowakowski M. Morphological and biochemical alterations of macrophages produced by a glycan, PSK. Immunopharmacology 1988:16 89–96.

    PubMed  Google Scholar 

  14. Hosokawa M, Mizukoshi T, Morikawa K,et al. The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother 1986;22:181–5.

    PubMed  Google Scholar 

  15. Mickey DD, Carvalho L, Foulkes K. Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma. J Urol 1989;142:1594–8.

    PubMed  Google Scholar 

  16. Hirose K, Zachariae CO, Oppenheim JJ,et al. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 1990;9:475–83.

    PubMed  Google Scholar 

  17. Kikuchi Y, Kizawa I, Oomori K,et al. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res 1988;79:125–30.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery II, Tokai University, School of Medicine, Bohseidai, Isehara, 259-11, Kanagawa, Japan

    Toshio Mitomi M.D. &  Takashi Noto M.D.

  2. Department of Surgery II, Yokohama City University, Japan

    Shuji Tsuchiya M.D. & Kiyoshi Nishiyama M.D.

  3. Department of Surgery I, Yokohama City University, Japan

    Tomishige Amano M.D.

  4. Department of Surgery II, St. Marianna University School of Medicine, Japan

    Noboru Iijima M.D. & Kazumitsu Oya M.D.

  5. Kanto Teishin Hospital, Japan

    Koichi Aso M.D. & Hisashi Oka M.D.

  6. Department of Surgery, Showa University School of Medicine, Fujigaoka Hospital, Japan

    Kaisuke Suzuki M.D.

  7. Department of Surgery, Sagamihara National Hospital, Japan

    Toshitake Takahashi M.D.

  8. Keiyu General Hospital, Japan

    Norihisa Murayama M.D.

  9. Department of Pharmacology, Ehime University School of Medicine, Japan

    Nobuya Ogawa M.D.

Authors
  1. Toshio Mitomi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuji Tsuchiya M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noboru Iijima M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichi Aso M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaisuke Suzuki M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kiyoshi Nishiyama M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomishige Amano M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshitake Takahashi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Norihisa Murayama M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hisashi Oka M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazumitsu Oya M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takashi Noto M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nobuya Ogawa M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dr. Suzuki is deceased.

About this article

Cite this article

Mitomi, T., Tsuchiya, S., Iijima, N. et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK® in curatively resected colorectal cancer. Dis Colon Rectum 35, 123–130 (1992). https://doi.org/10.1007/BF02050666

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02050666

Key words

Search

Navigation